WinstonWınston
Back
Stock

Oryzon Genomics S.A.

0RDB.L
Biotechnology · Healthcare
Price
2.67 GBp
+0.01 (+0.30%)
Market Cap
£207.0M
Exchange
London Stock Exchange
Winston Score
–
Winston looking sleepy
No score yet — Winston is napping.
We couldn’t gather enough financial data to score this stock reliably.
Track this stock — start free trial

Share count rising — dilution

+40.9% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 52.8M (2021) → 74.4M (2025)

§Winston Score History

The full picture

Oryzon Genomics is a Spanish biotech company that develops drugs targeting serious brain and blood diseases. Its main focus is on medicines that block a protein called LSD1, which plays a role in certain cancers and neurological conditions like schizophrenia and multiple sclerosis. The company's lead drug candidates include iadademstat and vafidemstat, which are being tested in clinical trials.

Oryzon earns revenue primarily through research collaborations and licensing deals with larger pharmaceutical companies, rather than selling approved products yet. It is headquartered in Barcelona, Spain, and operates mainly in Europe, with a small market cap of around $200 million. The company's deep expertise in epigenetics — the science of how genes are switched on and off — gives it a specialized edge, but its biggest risk is that it is spending far more than it earns, and its financial future depends heavily on whether its drug candidates succeed in clinical trials and attract larger partners or regulatory approval.

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

-100.0% YoY

YoY Growth Rate

Revenue declining

EPS Growth

-340.0% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$15M/ year

↑ Rising (+141% vs prior year)

R&D investment increasing — building for the future

Insider Activity

20.8%ownership

→ Flat

Insider ownership roughly steady over the past year

Cash Position

Cash flow positive

$17M cash & investments

Company generates more cash than it spends — no dilution risk from fundraising

Revenue declining

Oryzon Genomics S.A.'s revenue is actually shrinking. In a growth stock, that removes the core investment thesis. The low Winston Score here may be warranted — unless there's a turnaround story.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Profit per sale
Gross Margin
N/A
Data not available
Profit after running costs
Operating Margin
N/A
Data not available
Return on the money invested
ROCE
-10.1%
Weak — -10.1% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales growth
Sales YoY
-100.0%
Shrinking sales (-100.0% YoY)
Profit growth
EPS YoY
N/A
Data not available
How steady the profit is
EPS Consistency
3/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Profit that turns into cash
Cash Conversion
N/A
Data not available
Spare cash per sale
FCF Margin
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

What it owes vs what it owns
Debt / Equity
0.06
Conservative — low debt load (0.06)
Covers its interest
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

Price vs profit
P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
Cheaper or dearer next year
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Dividend
Dividend Yield
42.07%
Healthy income — 42.07% yield

Yield above 6% — often a flag the market is pricing in a cut.

Dividend record
Dividend Growth
N/A
no trend
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial